And there are many other tools, lessons learned, for those treating the most seriously ill coronavirus patients.
"Now we have a lot more information, number one, about the virus and how it acts," said Dr. Andra Blomkalns, Chair of the Department of Emergency Medicine at Stanford, "and then also some additional treatment potentials, most notably the monoclonal antibodies from Lilly and Regeneron and those are given early in the course of the disease, before the patient needs to be hospitalized."
"Despite the challenges of treating so many COVID patients here over the past 10 months, doctors are confident the tools and knowledge gained during that time will be lifesaving long after the pandemic is over."